



Investment Process

We seek to invest in companies, within our preferred themes, with sustainable growth characteristics at attractive valuations that do not fully reflect their long-term potential.

Themes

We identify long-term secular growth trends with the objective of investing in companies that have meaningful exposure to these trends. Our fundamental analysis focuses on those industry leaders with attractive growth and valuation characteristics that will be long-term beneficiaries of any structural change and/or trend.

Sustainable Growth

We apply a fundamental approach to identifying the long-term, sustainable growth characteristics of potential investments. We seek high-quality companies that typically have a sustainable competitive advantage, a superior business model and a high-quality management team.

Valuation

We use multiple valuation metrics to establish a target price range. We assess the relationship between our estimate of a company's sustainable growth prospects and its current valuation.

Team Overview

Our team approach combines the benefits of strong leadership with the creative ideas of a deep and highly experienced team of research analysts. We believe this approach allows us to leverage a broad set of perspectives into dynamic portfolios.

Portfolio Management



Mark L. Yockey, CFA
Portfolio Manager



Charles-Henri Hamker
Portfolio Manager



Andrew J. Euretig
Portfolio Manager

Investment Results (% USD)

As of 30 September 2020	Average Annual Total Returns						
	QTD	YTD	1 Yr	3 Yr	5 Yr	10 Yr	Inception ¹
Composite — Gross	9.15	13.96	22.79	16.24	15.57	14.20	13.74
Composite — Net	8.91	13.21	21.70	15.14	14.46	13.09	12.63
MSCI All Country World Index	8.13	1.37	10.44	7.11	10.29	8.54	8.17

Annual Returns (% USD) 12 months ended 30 September

	2016	2017	2018	2019	2020
Composite — Gross	8.96	20.52	18.36	8.12	22.79

Source: Artisan Partners/MSCI. Returns for periods less than one year are not annualized. ¹Composite inception: 1 April 2010.

Past performance does not guarantee and is not a reliable indicator of future results. Current performance may be lower or higher than the performance shown. Composite performance has been presented in both gross and net of investment management fees.

Investment Risks: Investments will rise and fall with market fluctuations and investor capital is at risk. Investors investing in strategies denominated in non-local currency should be aware of the risk of currency exchange fluctuations that may cause a loss of principal. These risks, among others, are further described near the back of this document, which should be read in conjunction with this material.



Investing Environment

Following Q2's historic rebound, the recovery in global equities continued in Q3 as earnings results came in better than feared. Returns were led by the more economically sensitive industrials, materials and consumer discretionary sectors, reflecting optimism regarding recovering economic indicators and progress on a COVID-19 vaccine. Financials and energy stocks were the worst performers, finishing lower. Certainly, asset prices broadly have been buttressed by the notions that central banks have investors' backs if volatility were to reemerge and additional fiscal support is in the offing. Regionally, both developed and emerging markets turned in high single-digit returns in Q3. In the developed world, the US outperformed Japan and Europe. Emerging markets were paced by double-digits gains in China and India.

Currency movements were favorable for USD-based returns in Q3. The appreciation of all other G10 currencies versus the US dollar owed to markets' pricing a protracted period of low or negative US real interest rates amid record US budget deficits and a shift in Federal Reserve policy toward acceptance of higher inflation. The euro was also lifted by the European Union's agreement in July to a €750 billion joint stimulus plan representing a historic step toward greater fiscal integration among the 27-nation bloc as it seeks to bolster its economy and avoid another debt crisis.

Perhaps no topic among investors has received more interest over the past year than the extreme performance dispersion between growth and value stocks. Growth stocks have led for most of the current market cycle that began after the global financial crisis, but growth's dominance has intensified of late. The MSCI ACWI Growth Index gained 12% in Q3, beating the MSCI ACWI Value Index by more than 800bps, and year to date this margin is more than a staggering 3200bps. Over the past three and five years, the growth index has outperformed its value counterpart by more than 1600bps and 1000bps per annum, respectively. The dynamics favoring growth are well understood; investors are willing to pay up for growth in an environment where growth is scarce and interest rates are low or even negative.

While we are growth investors, we are not growth "at any price" investors. A key facet of our approach is our valuation discipline. We seek to invest in companies with sustainable growth characteristics selling at attractive valuations. We are GARP (growth at a reasonable price) investors. So, while our growth orientation has aided our relative performance in recent years compared to broad global equity indices, our valuation discipline and unwillingness to chase growth at any price has made it tough to keep pace with growth-style indices. Rather than try to second-guess style rotations, we prefer to adhere to bottom-up, fundamental company analysis. Therefore, we will maintain our investment discipline and commitment to an investment approach that has been shown to perform well over varied market environments and add value over the long term.

Performance Discussion

Our portfolio outperformed the MSCI AC World Index, adding to its YTD lead. Among our top Q3 contributors were Immunomedics, Vertiv Holdings and Wuliangye Yibin. Immunomedics (IMMU), a stock we purchased in Q2, is a clinical-stage biopharmaceuticals company focused on the development of monoclonal antibody-based treatments for cancer. The stock shot higher when Gilead Sciences announced it was acquiring IMMU for approximately \$21 billion—an 108% premium to the stock's prior closing price. Our investment case was IMMU's lead cancer drug Trodelvy™, which received FDA approval for metastatic triple-negative breast cancer in April, would beat consensus sales projections based on its robust efficacy profile and the lack of other effective treatments. We also believe Trodelvy™ has the potential to work across multiple cancers. After the stock shot higher on the deal announcement, we sold our position in favor of better opportunities.

Vertiv is a leading provider of power, thermal and infrastructure management equipment and solutions for the global data center market. Vertiv is a unique asset in the structurally growing data center industry. Formerly a private company and before that a part of Emerson, Vertiv was recently purchased by GS Acquisition Holdings. Given new management's strong track record as operators, we believe there is substantial margin-expansion potential. Profits have been resilient despite top-line weakness amid the global pandemic because management has done a tremendous job taking out costs, driving margins higher. In addition to margin improvement potential, we believe the company is well-positioned to benefit from the secular growth in data traffic and is attractively valued relative to its growth.

Wuliangye Yibin is China's second-largest spirits maker by market value and one of only two truly national baijiu brands. Shares sold off in late January when news of COVID-19 broke, offering an attractive entry point, with the stock selling for a ~25% discount to key competitor Kweichow Moutai. Despite the February lockdown, we believed the company could grow sales mid- to high-single digits, driven by a recent price hike and resilient consumer demand given its premium brand power. Sales and earnings growth have exceeded our expectations, with 1H20 revenue and net profit growth in the mid-teens.

Our biggest detractors included health care holdings ACADIA Pharmaceuticals, Idorsia and STAAR Surgical. ACADIA is a biopharmaceuticals company and maker of Nuplazid® (pimavanserin), the only approved treatment for Parkinson's disease psychosis. Its phase III trial for Nuplazid® for depression missed its primary endpoint. ACADIA does not plan to conduct another trial in this indication. Despite this outcome, we believe Nuplazid's label expansion to dementia psychosis—a large market opportunity that currently does not have any other approved drugs—remains likely.

Idorsia is a Swiss biotechnology company that was spun off from Actelion in 2017. The company has a broad clinical development pipeline, with several phase III proprietary programs in the areas of insomnia, resistant hypertension management and Fabry disease, among others. Shares fell on mixed results for its second phase III study for lead pipeline asset daridorexant for the treatment of insomnia, as statistical significance was not found at the lower dose. However, we still see a high probability of the combined phase III dataset supporting approval for the higher dose.

STAAR Surgical is a developer of vision correction products. Shares fell on a short seller's report alleging a material overstatement of revenue and profit in the company's China operations. After the report was published, we spoke with management straightaway regarding these allegations. We came away from that meeting without the necessary conviction to stay invested given the possibility of fraudulent reporting and sold our position in favor of better opportunities.

Positioning

Although the ongoing pandemic has changed the nature of our daily schedules as industry conferences and in-person meetings have been replaced with videoconferences, our discovery engine is working. We added several new holdings in Q3. Among the largest new positions were CM.com, Illumina and Johnson Controls. CM.com is a Netherlands-based provider of CPaaS (communication platform as a service), one of the world's fastest growing software categories. CM.com's software lets developers easily add mobile-based messaging and phone/voice functionality to their applications. We see revenue growth accelerating as the company pursues this large untapped market opportunity, utilizing its February 2020 IPO proceeds to triple its sales and marketing headcount by 2022 and accelerate its international expansion.

Illumina is a leader in next-generation sequencing with an estimated 70% market share, positioning it well for the rapid growth of sequencing within the clinical setting. In September 2020, the company announced the acquisition of GRAIL, a pioneering developer of new technologies for early cancer detection. GRAIL's Galleri™ test has potential to disrupt the oncology market. Using a simple blood draw, this test can detect multiple cancers before patients are symptomatic and their cancer has metastasized—helping to diagnose patients in earlier stages with the highest probability of successful treatment and survival. This is a large market opportunity that we estimate is over \$30 billion in the US alone.

Johnson Controls is an operator in the building services market, providing building controls, HVAC systems, fire and safety, and power solutions. In a post-pandemic world, we believe new air quality standards and demand for touchless technologies will drive a new investment cycle in renovating existing commercial office buildings. In addition, Johnson Controls' solutions for enhancing buildings' energy efficiency and sustainability should see greater demand as government regulations and stimulus plans increasingly address the sources of climate change.

Besides our previously mentioned sales of Immunomedics and STAAR Surgical, we also sold La Francaise des Jeux, France's national lottery operator, and Varonis Systems, a data security and analytics software provider, as shares approached our target valuations.

Outlook

The current investment environment is unique in our experience in that economic and financial conditions are being driven by a public health crisis, rather than endogenous financial system forces. This started as a global health issue, and we believe it will continue to play out as one. Amid the pandemic, a global economy reliant on unprecedented levels of fiscal and monetary stimulus and potential geopolitical shifts due to the US election, Brexit and an emerging deglobalization trend, the world and financial markets are littered with uncertainty. Although equities have staged a swift comeback following one of the greatest selloffs in history, we believe the effects of COVID-19 will be felt for some time due to the "abundance of caution" many people will exhibit while progress continues on a vaccine. Hence, we expect the recovery will take longer than what we perceive is priced by markets and believe companies will need staying power to survive this period and come out stronger on the other side. We believe the winners that emerge will be companies that 1) provide essential goods and services, 2) possess unique assets, 3) offer value-added capabilities and 4) benefit from changing behavior.

Business Update

Ian Chua, an analyst on the team, is no longer employed by Artisan Partners effective September 18, 2020. Ian conducted multi-sector research, primarily focusing on disruptive business models in the Asia Pacific region. We wish him well in his future endeavors and thank him for his contributions. Coverage of existing holdings has been assumed by other team members.

In September, the team added Joe Del Gaudio as a multi-sector analyst. Prior to joining Artisan Partners, Mr. Del Gaudio was an equity research analyst at Neuberger Berman where he was a generalist on the global equities team covering the industrials, technology and consumer sectors. Earlier in his career, he was an equity analyst focusing on technology at Sanford C. Bernstein and a management consultant focusing on technology, industrials and transportation at Booz & Company.

ARTISAN CANVAS—NOW AVAILABLE

Timely insights and updates from our investment teams and firm leadership

Visit www.artisancanvas.com

For more information: Visit www.artisanpartners.com

Investment Risks: International investments involve special risks, including currency fluctuation, lower liquidity, different accounting methods and economic and political systems, and higher transaction costs. These risks typically are greater in emerging markets. Securities of small- and medium-sized companies tend to have a shorter history of operations, be more volatile and less liquid and may have underperformed securities of large companies during some periods. Growth securities may underperform other asset types during a given period. These risks, among others, are further described in Artisan Partners Form ADV, which is available upon request.

Unless otherwise indicated, the Artisan Strategy characteristics relate to that of an investment composite or a representative account managed within a composite. It is intended to provide a general illustration of the investment strategy and considerations used by Artisan Partners in managing that strategy. Individual accounts may differ, at times significantly, from the reference data shown due to varying account restrictions, fees and expenses, and since-inception time periods, among others. Where applicable, this information is supplemental to, and not to be construed with, a current or prospective client's investment account information. References to individual security performance relate to a representative account in the composite. Individual holding periods may differ.

Securities referenced may not be representative of all portfolio holdings. Securities of the same issuer are aggregated to determine a holding's portfolio weight. Portfolio statistics calculations exclude outlier data and may substitute information from a related security if unavailable for a particular security. This material is as of the date indicated and is subject to change without notice. Totals may not sum due to rounding.

Attribution is used to evaluate the investment management decisions which affected the portfolio's performance when compared to a benchmark index. Attribution is not exact, but should be considered an approximation of the relative contribution of each of the factors considered.

Net-of-fees composite returns were calculated using the highest model investment advisory fees applicable to portfolios within the composite. Fees may be higher for certain pooled vehicles and the composite may include accounts with performance-based fees. All performance results are net of commissions and transaction costs, and have been presented gross and net of investment advisory fees. Dividend income is recorded net of foreign withholding taxes on ex-dividend date or as soon after the ex-dividend date as the information becomes available to Artisan Partners. Interest income is recorded on the accrual basis. Performance results for the Index include reinvested dividends and are presented net of foreign withholding taxes but, unlike the portfolio's returns, do not reflect the payment of sales commissions or other expenses incurred in the purchase or sale of the securities included in the indices.

MSCI All Country World Index measures the performance of developed and emerging markets. MSCI All Country World Growth Index measures the performance of companies in developed and emerging markets with higher forecasted and historical growth rates. MSCI All Country World Value Index measures the performance of companies in developed and emerging markets with lower price/book and forward price/earnings ratios. The index(es) are unmanaged; include net reinvested dividends; do not reflect fees or expenses; and are not available for direct investment.

MSCI makes no express or implied warranties or representations and shall have no liability whatsoever with respect to any MSCI data contained herein. The MSCI data may not be further redistributed or used to create indices or financial products. This report is not approved or produced by MSCI.

The Global Industry Classification Standard (GICS[®]) is the exclusive intellectual property of MSCI Inc. (MSCI) and Standard & Poor's Financial Services, LLC (S&P). Neither MSCI, S&P, their affiliates, nor any of their third party providers ("GICS Parties") makes any representations or warranties, express or implied, with respect to GICS or the results to be obtained by the use thereof, and expressly disclaim all warranties, including warranties of accuracy, completeness, merchantability and fitness for a particular purpose. The GICS Parties shall not have any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of such damages.

This summary represents the views of the portfolio manager as of 30 Sep 2020. Those views and portfolio holdings are subject to change and Artisan Partners disclaims any obligation to advise investors of such changes. The discussion of portfolio holdings does not constitute a recommendation of any individual security. For a complete list of holdings by contribution to the strategy, refer to the Contributors to Return chart.

This material is provided for informational purposes without regard to your particular investment needs. This material shall not be construed as investment or tax advice on which you may rely for your investment decisions. Investors should consult their financial and tax adviser before making investments in order to determine the appropriateness of any investment product discussed herein. In no event shall Artisan Partners have any liability for direct, indirect, special, incidental, punitive, consequential (including, without limitation, lost profits) losses or any other damages resulting from the use of this material.

Artisan Partners Limited Partnership (APLP) is an investment adviser registered with the U.S. Securities and Exchange Commission (SEC). Artisan Partners UK LLP (APUK) is authorized and regulated by the Financial Conduct Authority and is a registered investment adviser with the SEC. APEL Financial Distribution Services Limited (AP Europe) is authorized and regulated by the Central Bank of Ireland. APLP, APUK and AP Europe are collectively, with their parent company and affiliates, referred to as Artisan Partners herein. Artisan Partners is not registered, authorized or eligible for an exemption from registration in all jurisdictions. Therefore, services described herein may not be available in certain jurisdictions. This material does not constitute an offer or solicitation where such actions are not authorized or lawful, and in some cases may only be provided at the initiative of the prospect. Further limitations on the availability of products or services described herein may be imposed.

This material is only intended for investors which meet qualifications as institutional investors as defined in the applicable jurisdiction where this material is received, which includes only *Professional Clients* or *Eligible Counterparties* as defined by the Markets in Financial Instruments Directive (MiFID) where this material is issued by APUK or AP Europe. This material is not for use by retail investors and may not be reproduced or distributed without Artisan Partners' permission.

In the United Kingdom, issued by APUK, 25 St. James's St., Floor 3, London SW1A 1HA, registered in England and Wales (LLP No. 0C351201). Registered office: Reading Bridge House, Floor 4, George St., Reading, Berkshire RG1 8LS. In Ireland, issued by AP Europe, Fitzwilliam Hall, Fitzwilliam Pl, Ste. 202, Dublin 2, D02 T292. Registered office: 70 Sir John Rogerson's Quay, Dublin 2, D02 R296 (Company No. 637966).

Australia: This material is directed at wholesale clients only and is not intended for, or to be relied upon by, private individuals or retail investors. Artisan Partners Australia Pty Ltd is a representative of APLP (ARBN 153 777 292) and APUK (ARBN 603 522 649). APLP and APUK are respectively regulated under US and UK laws which differ from Australian laws and are exempt from the requirement to hold an Australian financial services license under the Australian Corporations Act 2001 in respect to financial services provided in Australia.

Bailiwick of Guernsey: The financial services referred to in this material and this document are not being made available in the Bailiwick of Guernsey (Guernsey) to more than 50 persons in Guernsey and the financial services may not be accepted by more than 50 persons in Guernsey.

Canada: This material is distributed in Canada by APLP and/or Artisan Partners Distributors LLC, which conduct activities in Canada under exemptions from the dealer, portfolio manager and investment fund manager registration requirements of applicable Canadian securities laws. This material does not constitute an offer of services in circumstances where such exemptions are not available. APLP advisory services are available only to investors that qualify as "permitted clients" under applicable Canadian securities laws.

© 2020 Artisan Partners. All rights reserved.

For Institutional Investors — Not for Onward Distribution

A R T I S A N



P A R T N E R S

Artisan Global Equity Strategy

Quarterly Contribution to Return (% USD)

As of 30 September 2020

Top Contributors	Average Weight	Contribution to Return	Ending Weight
Immunomedics Inc	1.05	1.64	0.00
Vertiv Holdings Co	2.88	0.70	3.41
Amazon.com Inc	3.50	0.52	3.21
Natera Inc	1.24	0.51	1.57
Wuliangye Yibin Co Ltd	1.56	0.50	1.08
Alibaba Group Holding Ltd	1.50	0.44	2.23
Linde PLC	3.29	0.42	2.92
Clarivate PLC	1.23	0.42	1.38
Jeol Ltd	1.80	0.40	1.97
Varonis Systems Inc	1.10	0.32	0.00
AVEVA Group PLC	1.55	0.31	1.68
ViewRay Inc	0.66	0.31	0.83
Fidelity National Information Services Inc	3.05	0.30	3.03
Accelaron Pharma Inc	1.23	0.25	1.64
Medacta Group SA	1.50	0.25	1.48
Reliance Industries Ltd	0.84	0.23	1.05
Genmab A/S	2.41	0.22	1.70
Mastercard Inc	1.47	0.20	1.49
Lonza Group AG	1.17	0.20	0.94
Blueprint Medicines Corp	0.74	0.20	1.32
Illumina Inc	0.16	0.20	1.94
Canadian Pacific Railway Ltd	0.98	0.18	1.07
Midea Group Co Ltd	0.74	0.17	0.77
Air Liquide SA	1.54	0.16	1.47
Nibe Industrier AB	1.00	0.15	1.07
Intercontinental Exchange Inc	1.55	0.15	1.47
T-Mobile US Inc	1.59	0.15	1.83
Synopsys Inc	1.49	0.14	1.35
Otis Worldwide Corp	1.61	0.14	1.75
OBIC Business Consultants Co Ltd	1.26	0.12	1.05
Thermo Fisher Scientific Inc	0.56	0.11	0.63
Scout24 AG	0.90	0.11	0.88
Microsoft Corp	2.52	0.10	3.04
Telefonaktiebolaget LM Ericsson	0.79	0.10	0.86
Siemens AG	0.64	0.09	0.77
Nestle SA	1.15	0.09	1.12
The TJX Cos Inc	0.90	0.09	0.91
Alphabet Inc	2.23	0.08	2.09
Coca-Cola European Partners PLC	0.47	0.08	0.00
Starbucks Corp	0.51	0.08	0.00
IHS Markit Ltd	1.38	0.07	1.25
Johnson Controls International PLC	0.90	0.07	1.47
Ascendis Pharma A/S	0.93	0.07	1.33
TMX Group Ltd	1.32	0.06	1.25
AIA Group Ltd	1.16	0.06	1.14
Boston Scientific Corp	0.77	0.06	0.00
Morningstar Inc	0.52	0.05	0.00
Eidos Therapeutics Inc	0.79	0.05	0.86
Argenx SE	0.09	0.05	0.70

Bottom Contributors	Average Weight	Contribution to Return	Ending Weight
STAAR Surgical Co	0.60	-0.31	0.00
ACADIA Pharmaceuticals Inc	1.67	-0.27	1.63
eHealth Inc	0.30	-0.26	0.00
Peijia Medical Ltd	0.68	-0.20	0.60
Cigna Corp	1.52	-0.18	1.11
Amarin Corp PLC	0.35	-0.16	0.08
Idorsia Ltd	0.78	-0.14	0.70
uniQure NV	0.61	-0.12	0.53
Ping An Healthcare and Technology Co Ltd	0.71	-0.10	0.27
Temenos AG	0.64	-0.08	0.54
SVMK Inc	1.35	-0.08	1.25
UCB SA	1.13	-0.07	1.44
PTC Therapeutics Inc	0.52	-0.07	0.00
Astellas Pharma Inc	0.67	-0.07	0.60
Deutsche Boerse AG	3.28	-0.07	2.93
Splunk Inc	0.93	-0.04	0.76
China International Capital Corp Ltd	0.34	-0.03	1.04
Halozyme Therapeutics Inc	2.86	-0.03	2.62
E.ON SE	0.84	-0.03	0.81
Grifols SA	0.20	-0.03	0.00
Deutsche Telekom AG	1.87	-0.02	1.86
Roche Holding AG	1.65	-0.01	1.55
Horizon Therapeutics PLC	0.04	-0.01	0.47
THG Holdings Ltd	0.01	-0.01	0.00
Vertex Pharmaceuticals Inc	0.24	-0.00	0.49
Berkeley Lights Inc	0.00	-0.00	0.00
JFrog Ltd	0.00	-0.00	0.00
Hoya Corp	0.00	-0.00	0.16
Snowflake Inc	0.00	-0.00	0.00
CM.com NV	0.08	-0.00	0.57
Adevinta ASA	0.02	0.00	0.09
Nuvei Corp	0.00	0.00	0.00
Li Auto Inc	0.01	0.00	0.00
Nongfu Spring Co Ltd	0.00	0.00	0.00
Obic Co Ltd	1.19	0.01	1.00
Unity Software Inc	0.00	0.01	0.00
MorphoSys AG	0.93	0.01	0.93
Cash Holdings	1.20	0.01	1.87
L3Harris Technologies Inc	1.35	0.01	1.24
Siemens Energy AG	0.01	0.02	0.19
La Francaise des Jeux SAEM	0.16	0.02	0.00
Carrier Global Corp	0.34	0.02	0.96
TeamSpirit Inc	0.33	0.02	0.69
Lamb Weston Holdings Inc	0.87	0.03	0.87
Six Flags Entertainment Corp	0.10	0.03	0.00
Kinaxis Inc	0.64	0.03	0.37
Bristol Myers Squibb Co	1.27	0.03	1.33
EDP - Energias de Portugal SA	0.84	0.04	0.81
Tencent Holdings Ltd	1.49	0.05	1.48
Workiva Inc	1.18	0.05	1.05

Source: Artisan Partners/FactSet. Performance is historical and is not a reliable indicator of future results. As of 30 Sep 2020. These investments made the greatest contribution to, or detracted most from, performance during the period based on a representative account within the strategy Composite. Upon request, Artisan will provide: (i) the calculation methodology and/or (ii) a list showing the contribution of each holding to overall performance during the measurement period. Securities of the same issuer are aggregated to determine the weight in the portfolio. % Contribution to Return is calculated by FactSet by multiplying a security's weight in the portfolio by its in portfolio return for the period referenced and does not take into account expenses of the portfolio. Purchases/sales are accounted for by using end of the day prices, which may or may not reflect the actual purchase/sale price realized by the portfolio.